51 related articles for article (PubMed ID: 6279280)
1. Implementation of micromethods to resolve problems of human breast tumor heterogeneity in analysis of cyclic 3':5'-nucleotide phosphodiesterase.
Larner EH; Rutherford CL
Cancer Res; 1982 May; 42(5):1661-8. PubMed ID: 6279280
[TBL] [Abstract][Full Text] [Related]
2. Taste bud adenosine -3'5'-monophosphate phosphodiesterase: activity, subcellular distribution and kinetic parameters.
Law JS; Henkin RI
Res Commun Chem Pathol Pharmacol; 1982 Dec; 38(3):439-52. PubMed ID: 6298918
[TBL] [Abstract][Full Text] [Related]
3. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
4. 3',5'-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition.
Drees M; Zimmermann R; Eisenbrand G
Cancer Res; 1993 Jul; 53(13):3058-61. PubMed ID: 8391385
[TBL] [Abstract][Full Text] [Related]
5. [Differences in the Ca2+- and calmodulin-sensitivity of cyclic nucleotide phosphodiesterase [PDE] in microtubule preparations from brain and Ehrlich-ascites-tumor cells [EAT]].
Künkel W; Römer W; Wohlrabe K
Acta Histochem Suppl; 1983; 27():311-6. PubMed ID: 6306728
[TBL] [Abstract][Full Text] [Related]
6. Multiple forms of cyclic nucleotide phosphodiesterase in a murine adrenal cortex cell line (Y-1).
Ryan JA; Toscano WA
Arch Biochem Biophys; 1985 Sep; 241(2):403-12. PubMed ID: 2994565
[TBL] [Abstract][Full Text] [Related]
7. Cyclic nucleotide-mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity. Selective effect of cyclic AMP.
Maurice DH
Cell Biochem Biophys; 1998; 29(1-2):35-47. PubMed ID: 9631237
[TBL] [Abstract][Full Text] [Related]
8. [Ca2+-calmodulin-activated cyclic nucleotide phosphodiesterase from the soluble fraction of the human brain: Kinetic properties and the effect of the antidepressant pyrazidol and its nitro analog on the enzyme].
Medvedeva MV; Belov AA; Kireeva NN; Bobruskin ID
Biokhimiia; 1993 May; 58(5):798-808. PubMed ID: 8393348
[TBL] [Abstract][Full Text] [Related]
9. Characterization of 3',5' cyclic nucleotide phosphodiesterase activity in Y79 retinoblastoma cells: absence of functional PDE6.
White JB; Thompson WJ; Pittler SJ
Mol Vis; 2004 Oct; 10():738-49. PubMed ID: 15480303
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.
Marko D; Romanakis K; Zankl H; Fürstenberger G; Steinbauer B; Eisenbrand G
Cell Biochem Biophys; 1998; 28(2-3):75-101. PubMed ID: 9515161
[TBL] [Abstract][Full Text] [Related]
11. Expression and characterization of deletion recombinants of two cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE-3).
He R; Komas N; Ekholm D; Murata T; Taira M; Hockman S; Degerman E; Manganiello VC
Cell Biochem Biophys; 1998; 29(1-2):89-111. PubMed ID: 9631240
[TBL] [Abstract][Full Text] [Related]
12. Cyclic AMP phosphodiesterase (PDE) in microtubule preparations. I. The influence of calmodulin and Ca2+ on the PDE activity.
Künkel W; Römer W
Acta Histochem Suppl; 1983; 27():303-9. PubMed ID: 6306726
[No Abstract] [Full Text] [Related]
13. Properties of hepatic and pancreatic cyclic AMP phosphodiesterase in the cat.
Sakane Y; Morgan PR; Glenn TM
Res Commun Chem Pathol Pharmacol; 1981 Nov; 34(2):251-66. PubMed ID: 6278552
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors.
Karami-Tehrani F; Moeinifard M; Aghaei M; Atri M
Arch Med Res; 2012 Aug; 43(6):470-5. PubMed ID: 22960860
[TBL] [Abstract][Full Text] [Related]
15. Cyclic nucleotide phosphodiesterases in normal and malignant human tissues.
Stefanovich V; Ambrus JL; Ambrus CM; Karakousis C; Takita H
J Med; 1981; 12(4):243-50. PubMed ID: 6273486
[TBL] [Abstract][Full Text] [Related]
16. Identification and stabilization of large molecular weight PDE-IVs from U937 cells.
DiSanto ME; Heaslip RJ
Biochem Biophys Res Commun; 1993 Dec; 197(3):1126-31. PubMed ID: 8280127
[TBL] [Abstract][Full Text] [Related]
17. Reduction in cyclic 3',5'-adenosine monophosphate phosphodiesterase activity in exudate and cultured mouse peritoneal macrophages.
Zendegui JG; Klein TW
J Reticuloendothel Soc; 1982 Jun; 31(6):455-67. PubMed ID: 6288938
[TBL] [Abstract][Full Text] [Related]
18. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
19. Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Biochem Pharmacol; 2005 Jan; 69(2):267-75. PubMed ID: 15627479
[TBL] [Abstract][Full Text] [Related]
20. Plasma membrane-bound cyclic AMP phosphodiesterase activity in 3T3-L1 adipocytes.
Zhang X; Carey GB
Comp Biochem Physiol B Biochem Mol Biol; 2004 Mar; 137(3):309-16. PubMed ID: 15050518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
